MicroSurgical Technology acquires glaucoma assets from NeoMedix

MicroSurgical Technology has acquired the glaucoma-related assets of NeoMedix, according to a press release.

The assets include the surgical platforms Trabectome and Goniotome, which are indicated for treatment of pediatric and adult open- or narrow-angle glaucoma, primary or secondary glaucoma, and pseudoexfoliative or non-pseudoexfoliative glaucoma.

Trabectome promotes sustained IOP reduction through electrosurgical ablation to remove the trabecular meshwork. Goniotome excises the trabecular meshwork using serrated blades, while Goniotome I/A helps maintain a stable, clear anterior chamber while improving angle visualization.

“These products provide MST with a solid entry into the MIGS space while we continue to advance our offerings in complex cataract solutions,” Ramin Mojdeh, president of MST, said in the release.

MicroSurgical Technology has acquired the glaucoma-related assets of NeoMedix, according to a press release.

The assets include the surgical platforms Trabectome and Goniotome, which are indicated for treatment of pediatric and adult open- or narrow-angle glaucoma, primary or secondary glaucoma, and pseudoexfoliative or non-pseudoexfoliative glaucoma.

Trabectome promotes sustained IOP reduction through electrosurgical ablation to remove the trabecular meshwork. Goniotome excises the trabecular meshwork using serrated blades, while Goniotome I/A helps maintain a stable, clear anterior chamber while improving angle visualization.

“These products provide MST with a solid entry into the MIGS space while we continue to advance our offerings in complex cataract solutions,” Ramin Mojdeh, president of MST, said in the release.